News Column

RXi Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference

February 17, 2014



By a News Reporter-Staff News Editor at Pharma Business Week -- RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, announced that the Company's President & CEO, Dr. Geert Cauwenbergh, will present at the 16(th) Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 11:30am EST. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's sd-rxRNA technology platform (see also RXi Pharmaceuticals Corporation).

The presentation will be available on the "Investors" section of the Company's website, www.rxipharma.com.

The 16(th) Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. The conference will take place February 10-11 at the Waldorf Astoria in New York City.

Keywords for this news article include: RXi Pharmaceuticals Corporation.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Pharma Business Week


Story Tools